AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02757521
Drug: Nitrous Oxide
RxNorm normalized name: Nitrous Oxide
DrugBank: Nitrous oxide (DB06690)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50% nitrous oxide/ 50% oxygen, 3 one hour inhalation treatments per Stage, every other day (M,W,F)
Trial: NCT01365533
Drug: Roflumilast
RxNorm normalized name: Roflumilast
DrugBank: Roflumilast (DB01656)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Roflumilast 500 μg, one tablet once daily, orally
Trial: NCT00436579
Drug: sorafenib tosylate
RxNorm normalized name: Sorafenib Tosylate
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given orally
Trial: NCT01231685
Drug: Raltegravir
RxNorm normalized name: Raltegravir
DrugBank: Raltegravir (DB06817)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subjects will maintain their nucleoside backbone and switch ritonavir-boosted protease inhibitor to Raltegravir 400 mg po BID for 48 weeks.
Trial: NCT01231685
Drug: Ritonavir-boosted protease inhibitor
RxNorm normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subjects will maintain their nucleoside backbone and remain on a ritonavir-boosted protease inhibitor at standard doses for for 48 weeks
Trial: NCT00000517
Drug: warfarin
RxNorm normalized name: Warfarin
DrugBank: Warfarin (DB00682)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00902941
Drug: Azilect 1mg
RxNorm normalized name: Azilect 1mg Tablet
DrugBank: Rasagiline (DB01367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1 mg daily orally for 120 days
Trial: NCT00692458
Drug: Comparator: odanacatib
DrugBank: Odanacatib (DB06670)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: odanacatib; 5mg oral, once daily for approximately 60 months.
Trial: NCT02737423
Drug: cholecalciferol
RxNorm normalized name: Cholecalciferol
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Effect of Vitamin D on the symptoms of diabetic neuropathy
Trial: NCT05037253
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be randomised to receive either high dose vitamin D (50,000 IU weekly) on the first and second week, followed by a switch to a daily intake of 5,000 IU for 3 months or low dose vitamin D (2,000 IU weekly) for 3 months.
Trial: NCT05111743
Drug: Brolucizumab
RxNorm normalized name: Brolucizumab
DrugBank: Brolucizumab (DB14864)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants received brolucizumab injection during the index period
Trial: NCT00904709
Drug: tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: After The starting dose of tranexamic acid will be 500 mg twice daily beginning the first day of menstrual flow for a total of 6 days per menstrual cycle. If after 2 days there is still menorrhagia without significant side effects the will be increased. The women will be assessed again at day 4 and 9 and dose escalation will continue until they have reached the optimal dose.The dose of tranexamic acid will be increased as follows: 1000 mg twice daily, 1000 mg three times daily, 1500 mg/1000 mg/1000 mg, 1000 mg four times daily, 1500 mg three times daily, and 1500 mg four times daily (maximum dose).Each patient will be followed for a minimum of one menstrual cycle and a maximum of 3 cycles.
Trial: NCT00827736
Drug: ISDN ointment
DrugBank: Isosorbide dinitrate (DB00883)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: application of ISDN 1% ointment 6 times a day
Trial: NCT02096614
Drug: TBI-1201
RxNorm normalized name: TBI-223
DrugBank: TBI-223 (DB18911)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TBI-1201(5\*10\^8 or 5\*10\^9) is administered.
Trial: NCT01126697
Drug: Coenzyme Q10 and Lisinopril
DrugBank: Lisinopril (DB00722)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Arm 1. Coenzyme Q10: taken once a day each morning by mouth OR Arm 2. Lisinopril: taken once a day each morning by mouth OR Arm 3. Coenzyme Q10 and lisinopril: each taken once a day in the morning by mouth OR Arm 4. Enhanced Standard Care (more doctor visits, muscle and breathing testing, and x-rays for monitoring, but no study medication).
Trial: NCT01309698
Drug: Vildagliptin (LAF237)
RxNorm normalized name: vildagliptin
DrugBank: Vildagliptin (DB04876)
FDA approved: no
EMA approved: yes
PMDA approved: no
Trial: NCT01309698
Drug: Voglibose
RxNorm normalized name: Voglibose
DrugBank: Voglibose (DB04878)
FDA approved: no
EMA approved: no
PMDA approved: yes
Trial: NCT01309698
Drug: Vildagliptin and Voglibose
RxNorm normalized name: vildagliptin
DrugBank: Vildagliptin (DB04876)
FDA approved: no
EMA approved: yes
PMDA approved: no
Trial: NCT00890890
Drug: Avagacestat
RxNorm normalized name: Avagacestat
DrugBank: Avagacestat (DB11893)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules, Oral, 50 mg, once daily, 104 - 220 Weeks
Trial: NCT00332969
Drug: Octreotide
RxNorm normalized name: Octreotide
DrugBank: Octreotide (DB00104)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02460055
Drug: propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: propofol 3mg/kg will be administered to facilitate endotracheal intubation
Trial: NCT02460055
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone 0.15mg/kg up to 20 mg will be used for anti-emesis prophylaxis
Trial: NCT02460055
Drug: Ondansetron
RxNorm normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ondansetron 0.15mg/kg up to 4mg will be used for anti-emesis prophylaxis
Trial: NCT02460055
Drug: sevoflurane, nitrous oxide and oxygen
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inhalational agents will be used to induce general anesthesia
Trial: NCT02096614
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fludarabine (20mg/m2 x 5 days Intravenous(IV)) is administered as pre-treatment medication of TBI-1201 in combination with cyclophosphamide.
Trial: NCT02398058
Drug: trabectedin
RxNorm normalized name: Trabectedin
DrugBank: Trabectedin (DB05109)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: trabectedin will be administered in a 24-h continuous i.v. infusion every 3 weeks
Trial: NCT02398058
Drug: olaparib
RxNorm normalized name: Olaparib
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: olaparib will be administered in a continuous daily dose every 12 hours
Trial: NCT03197103
Drug: N-Acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: For more information read Experimental Arm description
Trial: NCT01451736
Drug: paliperidone palmitate
RxNorm normalized name: Paliperidone Palmitate
DrugBank: Paliperidone (DB01267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: long-acting injectable
Trial: NCT01451736
Drug: risperidone
RxNorm normalized name: Risperidone
DrugBank: Risperidone (DB00734)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: oral
Trial: NCT06266598
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Only obese children with insulin resistance were treated with metformin.
Trial: NCT01931982
Drug: Victoza
RxNorm normalized name: Victoza
DrugBank: Liraglutide (DB06655)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT03682302
Drug: Exparel
RxNorm normalized name: Exparel
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EXPAREL 4mg/kg (maximum 266 mg)
Trial: NCT03682302
Drug: 0.5% Bupivacaine HCl
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bupivacaine HCl 2mg/kg
Trial: NCT03904225
Drug: Tegafur-Gimeracil-Oteracil
RxNorm normalized name: tegafur
DrugBank: Oteracil (DB03209)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: oral administration for 12 months
Trial: NCT01999972
Drug: axitinib
RxNorm normalized name: Axitinib
DrugBank: Axitinib (DB06626)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Axitinib: tablets, dosage range 2 - 5 mg, given orally twice daily on a continuous dosing schedule in 28 days cycles.
Trial: NCT01999972
Drug: crizotinib
RxNorm normalized name: Crizotinib
DrugBank: Crizotinib (DB08865)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Crizotinib: capsules, dosage range 200-250 mg, given orally twice daily or every day on a continuous dosing schedule in 28 days cycle.
Trial: NCT01999972
Drug: axitinib
RxNorm normalized name: Axitinib
DrugBank: Axitinib (DB06626)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Axitinib: tablets, dosage be defined based on Arm 1 results, given orally twice daily on a continuous dosing schedule in 28 days cycles.
Trial: NCT01999972
Drug: crizotinib
RxNorm normalized name: Crizotinib
DrugBank: Crizotinib (DB08865)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Crizotinib: capsules, dosage be defined based on Arm 1 results, given orally twice daily or every day on a continuous dosing schedule in 28 days cycle.
Trial: NCT01176461
Drug: Montanide ISA 51 VG
RxNorm normalized name: Montanide ISA 51 VG
DrugBank: Incomplete Freund's adjuvant (DB17475)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administer peptide vaccine emulsions prepared with Montanide® ISA 51 VG by deep subcutaneous injection.
Trial: NCT00009906
Drug: Imatinib Mesylate
RxNorm normalized name: Imatinib Mesylate
DrugBank: Imatinib (DB00619)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given orally
Trial: NCT02022722
Drug: Trigger Point Injections Triamcinolone Acetonide, Bupivacaine Hydrochloride
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The mixture is injected into the levator muscles, with half the volume on each side of the pelvic musculature.
Trial: NCT01127906
Drug: PF-04531083 100mg
RxNorm normalized name: cisplatin
DrugBank: Pf-04531083 (DB12468)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral PF-04531083 100mg suspension single dose
Trial: NCT01127906
Drug: PF-04531083 2000mg
RxNorm normalized name: Pf-04531083
DrugBank: Pf-04531083 (DB12468)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral PF-04531083 2000mg suspension single dose
Trial: NCT01127906
Drug: Oxycodone 20mg
RxNorm normalized name: oxycodone
DrugBank: Oxycodone (DB00497)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral Oxycodone 20mg (Oxycontin) controlled release formulation
Trial: NCT00932971
Drug: PEG-IFN alfa-2a, Tenofovir
DrugBank: Tenofovir (DB14126)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pegylated interferon alfa-2a, 180µg once weekly, subcutaneously; Tenofovir disoproxilfumarat, 245mg, once daily, orally
Trial: NCT00371059
Drug: Memantine
RxNorm normalized name: Memantine
DrugBank: Memantine (DB01043)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Memantine 10mg BD
Trial: NCT00953914
Drug: Pyridostigmine
RxNorm normalized name: Pyridostigmine
DrugBank: Pyridostigmine (DB00545)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pills containing 30 mg of Pyridostigmine will be orally administered 3 times daily for 1 day.
Trial: NCT03154359
Drug: Atomoxetine Hydrochloride
RxNorm normalized name: Atomoxetine Hydrochloride
DrugBank: Atomoxetine (DB00289)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atomoxetine dose adjusted to achieve pre-defined concentration
Trial: NCT02349945
Drug: follitropin alpha
RxNorm normalized name: follitropin alpha
DrugBank: Follitropin (DB00066)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: All subjects included in the study will receive recombinant FSH therapy (follitropin alpha: Gonal-f 150 I.U. s.c. every other day for 12 weeks). Follow up: 12 further weeks after end of treatment.~Previous studies included in the Cochrane meta-analysis used: hMG/hCG, 150 IU three times a week for 13 weeks; purified FSH, 150 IU/day for 12 weeks; rec hFSH, 150 IU/day for 12 weeks; rec hFSH, 100 IU on alternate days for 3 months. Therefore any dosage \> 100 IU on alternate days is eligible. The duration of treatment is based on the duration of one spermatogenetic cycle.
Trial: NCT01240889
Drug: Fluticasone
RxNorm normalized name: Fluticasone
DrugBank: Fluticasone (DB13867)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nasal spray
Trial: NCT01240889
Drug: Fluticason
RxNorm normalized name: Fluticason
DrugBank: Fluticasone (DB13867)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 sprays per day in each nostril
Trial: NCT01377415
Drug: bupivacaine
RxNorm normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: bupivacaine 5 mg/ml infusion 2 ml/h 48 h
Trial: NCT00439166
Drug: rifampicin
RxNorm normalized name: Rifampicin
DrugBank: Rifampin (DB01045)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: capsule, 300mg, o.d., daily for 11 months (administration starts in 2nd month of trial)
Trial: NCT00439166
Drug: Placebo matched to Rifampin
DrugBank: Rifampin (DB01045)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifampin-matched - red capsule, o.d., daily for 11 months starting at month 2.
Trial: NCT03634137
Drug: Afamelanotide Group 1
DrugBank: Afamelanotide (DB04931)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: One 16 mg bioresorbable afamelanotide implant (Group 1) from the previous manufacturing process.
Trial: NCT04439006
Drug: Ibrutinib
RxNorm normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given PO
Trial: NCT00174447
Drug: Ziprasidone
RxNorm normalized name: Ziprasidone
DrugBank: Ziprasidone (DB00246)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dosage may subsequently be adjusted according to clinical status, only at each protocol visit and step by step between 40, 60 and 80 mg bid
Trial: NCT01006525
Drug: zolpidem
RxNorm normalized name: Zolpidem
DrugBank: Zolpidem (DB00425)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: placebo or zolpidem (10mg)daily for one year
Trial: NCT03988010
Drug: Amantadine Sulfate
RxNorm normalized name: amantadine sulfate
DrugBank: Amantadine (DB00915)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 200mg/500ml i.v. solution for infusion
Trial: NCT03354637
Drug: ATI-50002 high dose
RxNorm normalized name: high-density polyethylene
DrugBank: Poly(lactic acid) (DB15037)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical solution
Trial: NCT03354637
Drug: ATI-50002 low dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Topical solution
Trial: NCT00232219
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04310332
Drug: 1L-PEG
RxNorm normalized name: PEG
DrugBank: Polyethylene glycol (DB09287)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The drug is 1L-PEG plus ascorbic acid (Plenvu®). It will be administered either the day before colonoscopy, or half the day before and half the day of colonoscopy, or the day of colonoscopy.~Patients are prescribed bowel prep according to local clinical practice and then all undergo colonoscopy. No standardized intervention on bowel prep is applied, as the design of the study is observational.
Trial: NCT04310332
Drug: 4L-PEG
RxNorm normalized name: PEG
DrugBank: Polyethylene glycol (DB09287)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The drug is 4L-PEG. It will be administered either the day before colonoscopy, or half the day before and half the day of colonoscopy, or the day of colonoscopy.~Patients are prescribed bowel prep according to local clinical practice and then all undergo colonoscopy. No standardized intervention on bowel prep is applied, as the design of the study is observational.
Trial: NCT03236610
Drug: tenofovir monotherapy
RxNorm normalized name: Tenofovir
DrugBank: Tenofovir (DB14126)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: switching to tenofovir monotherapy
Trial: NCT00358150
Drug: Eliglustat tartrate
RxNorm normalized name: eliglustat tartrate
DrugBank: Eliglustat (DB09039)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Eliglustat (Genz-112638) capsule as single 50 mg dose on Day 1 then eliglustat 50 mg twice daily (BID) from Day 2 to Day 19, then either eliglustat 50 mg BID (if Genz-99067\[active moiety of eliglustat in plasma\] trough plasma concentration was greater than or equal to \[\>=\]5 nanogram per milliliter \[ng/mL\] on Day 10) or eliglustat 100 mg BID(if Genz-99067 trough plasma concentration was less than \[\<\] 5 ng/mL), from day 20 to Year 4. After primary completion date (Week 52) participants underwent treatment interruption period of approximately 2 weeks before continuing same treatment through study completion (Year 9). Participant receiving 100 mg BID could be considered for further dose increase to 150 mg BID at Week 24 if they met certain criteria (for example, had been on treatment for at least 24 months, had not reached therapeutic goals established for participants receiving Cerezyme, and if all other causes for lack of treatment effect had been evaluated and ruled out).
Trial: NCT03236610
Drug: tenofovir plus entecavir combination
RxNorm normalized name: Entecavir
DrugBank: Entecavir (DB00442)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: continuing tenofovir plus entecavir
Trial: NCT01192789
Drug: Amoxicillin
RxNorm normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: LHWs treat severe pneumonia with oral amoxicillin at 90 mg/kg/day.
Trial: NCT03915080
Drug: Oktokog alpha
RxNorm normalized name: alpha tocopherol
DrugBank: Tocopherol (DB11251)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: adjusting dose and dose interval according to MyPKFIT
Trial: NCT01933503
Drug: OCA 10 mg
RxNorm normalized name: Ocaliva
DrugBank: Obeticholic acid (DB05990)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT01933503
Drug: OCA 25 mg
RxNorm normalized name: Ocaliva
DrugBank: Obeticholic acid (DB05990)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00003220
Drug: bryostatin 1
RxNorm normalized name: Bryostatin 1
DrugBank: Bryostatin 1 (DB11752)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00131963
Drug: paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given IV
Trial: NCT01047475
Drug: MB-6
RxNorm normalized name: MBS
DrugBank: Morpholinylmercaptobenzothiazole (DB14202)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6# TID with meal
Trial: NCT00485953
Drug: risedronate
RxNorm normalized name: Risedronate
DrugBank: Risedronic acid (DB00884)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: risedronate 35 mg per week
Trial: NCT01349413
Drug: Esomeprazole 20mg
RxNorm normalized name: ESOMEPRAZOLE 20MG (BASE) CAP,EC
DrugBank: Esomeprazole (DB00736)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral Esomeprazole 20mg daily for 8 weeks
Trial: NCT02772718
Drug: XOMA 358 single dose level B
RxNorm normalized name: Anti-STAT3 B VHH13 single domain antibody
DrugBank: SBT-100 (DB17215)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: XOMA 358 single dose level B administered by an intravenous infusion
Trial: NCT02772718
Drug: XOMA 358 multiple dose level 1
RxNorm normalized name: peanut allergenic extract
DrugBank: Peanut (DB10553)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: XOMA 358 multiple dose level 1 administered by an intravenous infusion
Trial: NCT00000177
Drug: Estrogen
RxNorm normalized name: Estrogen
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01812382
Drug: Retapamulin Microdialysis
RxNorm normalized name: Retapamulin
DrugBank: Retapamulin (DB01256)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: After a 30 minutes equilibration period of the microdialysis procedure/infusion with normal saline solution, 50nanogram (ng)/mL Retapamulin injectable solution will be infused at a flow rate of 1.5 microliter/minute over a period of 90 minutes. The total dose perfused for each of the 3 microdialysis tubes will be 6.75ng.
Trial: NCT03278886
Drug: Low dose naltrexone
DrugBank: Naltrexone (DB00704)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4.5 mg of low dose naltrexone taken once daily for 8 weeks
Trial: NCT03278886
Drug: Nalmefene
RxNorm normalized name: Nalmefene
DrugBank: Nalmefene (DB06230)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 18 mg of nalmefene taken once daily for 8 weeks
Trial: NCT00301483
Drug: Hemoglobin-based oxygen carrier-201 (HBOC 201)
RxNorm normalized name: Hemoglobin-based oxygen carrier 201 is purified, glutaraldehyde-polymerized, bovine hemoglobin, mw 250000
DrugBank: Hemoglobin (DB04945)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HBOC-201 is an investigational solution of sterile, ultrapurified, glutaraldehyde polymerized, modified bovine hemoglobin (Hb) in a balanced electrolyte solution. HBOC-201 has an Hb concentration of 12-14g/dL. HBOC-201 is an isosmotic solution that is stable for at least 36 months at 2-30ºC. It requires no reconstitution and can be administered directly into a peripheral or central vein. Blood typing is not required because all other cellular components, including the RBC membranes that carry the blood group antigens, have been removed.
Trial: NCT00126139
Drug: Abciximab
RxNorm normalized name: Abciximab
DrugBank: Abciximab (DB00054)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01039350
Drug: Darbepoetin alfa
RxNorm normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Darbepoetin alfa will be initiated at a weekly (QW) subcutaneous dose of 300 mcg over 8 weeks.
Trial: NCT00402545
Drug: Cetuximab
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given intravenously on days 1, 8 and 15 of each 21-day cycle for three cycles
Trial: NCT00402545
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given intravenously on day 1 of each 21-day cycle for 3 cycles
Trial: NCT00402545
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenously on day 1 of each 21-day cycle for 3 cycles
Trial: NCT00402545
Drug: 5-Fluorouracil
RxNorm normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given by continuous infusion pump over a period of 96 hours(dosage wil vary depending upon when participant enrolls in trial)